ABCL – AbCellera Biologics Inc.

Name : AbCellera Biologics Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $0.00000000000000

EPSttm :

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ABCL #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

ABCL — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

12.2

Margin Of Safety %

Put/Call OI Ratio

0.49

EPS Next Q Diff

0.01

EPS Last/This Y

-0.18

EPS This/Next Y

-0.09

Price

12.47

Target Price

Analyst Recom

1.14

Performance Q

20.33

Upside

-150.1%

Beta

1.59

Ticker: ABCL

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	ABCL	12.64	0.51	0.22	173951
2026-10-13	ABCL	12.61	0.51	0.55	173896
2026-10-14	ABCL	12.36	0.52	0.14	174155
2026-10-15	ABCL	12.68	0.52	0.31	174583
2026-10-16	ABCL	11.81	0.52	0.38	173704
2026-10-19	ABCL	11.94	0.45	0.04	126059
2026-10-20	ABCL	11.7	0.44	0.55	127518
2026-10-21	ABCL	12.23	0.44	0.37	128790
2026-10-22	ABCL	11.39	0.44	0.11	129782
2026-10-23	ABCL	11.82	0.44	0.04	132027
2026-10-26	ABCL	12.06	0.44	0.27	132646
2026-10-27	ABCL	12.85	0.44	0.13	133048
2026-10-28	ABCL	13.64	0.44	0.06	134252
2026-10-29	ABCL	13.08	0.43	0.96	136705
2026-10-30	ABCL	12.27	0.44	0.34	135140
2026-11-02	ABCL	11.11	0.44	1.77	136421
2026-11-03	ABCL	12.18	0.48	0.53	139407
2026-11-04	ABCL	12.28	0.48	0.12	139574
2026-11-05	ABCL	11.11	0.48	0.49	139816
2026-11-06	ABCL	11.89	0.48	0.19	139481
2026-11-09	ABCL	12.47	0.48	0.52	139686
2026-11-10	ABCL	12.47	0.49	0.88	140864
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	ABCL	12.64	7.4	-	-0.68
2026-10-13	ABCL	12.66	7.4	-	-0.68
2026-10-14	ABCL	12.37	7.4	-	-0.68
2026-10-15	ABCL	12.68	6.5	-	-0.67
2026-10-16	ABCL	11.80	6.5	-	-0.67
2026-10-19	ABCL	11.94	6.5	-	-0.67
2026-10-20	ABCL	11.94	6.5	-	-0.67
2026-10-21	ABCL	11.70	6.5	-	-0.67
2026-10-22	ABCL	11.39	6.5	-	-0.67
2026-10-23	ABCL	11.82	6.5	-	-0.67
2026-10-26	ABCL	12.07	6.5	-	-0.67
2026-10-27	ABCL	12.85	6.5	-	-0.67
2026-10-28	ABCL	13.64	6.5	-	-0.67
2026-10-29	ABCL	13.09	6.5	-	-0.67
2026-10-30	ABCL	12.27	6.5	-	-0.67
2026-11-02	ABCL	11.12	6.5	-	-0.67
2026-11-03	ABCL	12.18	6.5	-	-0.67
2026-11-04	ABCL	12.28	6.5	-	-0.67
2026-11-05	ABCL	11.11	6.5	-	-0.67
2026-11-06	ABCL	11.88	6.5	-	-0.67
2026-11-09	ABCL	12.48	6.5	-	-0.67
2026-11-10	ABCL	12.47	6.5	-	-0.67
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	ABCL	0.00	-5.03	12.82
2026-10-13	ABCL	0.00	-5.03	12.82
2026-10-14	ABCL	0.00	-5.03	12.82
2026-10-15	ABCL	0.00	-5.03	12.82
2026-10-16	ABCL	0.00	-5.03	12.82
2026-10-19	ABCL	0.00	-5.07	12.82
2026-10-20	ABCL	0.00	-5.07	12.82
2026-10-21	ABCL	0.00	-5.07	12.82
2026-10-22	ABCL	0.00	-5.07	12.82
2026-10-23	ABCL	0.00	-5.07	12.82
2026-10-26	ABCL	0.00	-6.06	12.82
2026-10-27	ABCL	0.00	-6.06	12.20
2026-10-28	ABCL	0.00	-6.06	12.20
2026-10-29	ABCL	0.00	-6.06	12.20
2026-10-30	ABCL	0.00	-6.06	12.20
2026-11-02	ABCL	0.00	-6.13	12.20
2026-11-03	ABCL	0.00	-6.13	12.20
2026-11-05	ABCL	0.00	-6.13	12.20
2026-11-06	ABCL	0.00	-6.13	12.20
2026-11-09	ABCL	0.00	-3.90	12.20
2026-11-10	ABCL	0.00	-3.90	12.20
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ABCL 589 360 ]

Last Quarter Act. EPS

-0.18

Avg. EPS Est. Current Quarter

-0.18

Avg. EPS Est. Next Quarter

-0.17

Insider Transactions

Institutional Transactions

-3.9

Beta

1.59

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

25.6

Max Drawdown 5-Year %

-88.2

Target Price

P/E

Forward P/E

PEG

P/S

59.5

P/B

3.83

P/Free Cash Flow

EPS

-0.48

Average EPS Est. Cur. Y

-0.67

EPS Next Y. (Est.)

-0.76

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-218.54

Relative Volume

0.63

Return on Equity vs Sector %

-44.7

Return on Equity vs Industry %

-25

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ABCL 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ABCL 589 450 ]

◆ ABCL Healthcare

$12.46

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

8/20

Pullback

17/25

Volume

6/15

Valuation

9/20

TP/AR

6/10

Options

7/10

RSI

51.6

Range 1M

46.1%

Sup Dist

4.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

6/25

Growth

11/30

Estimates

4/20

Inst/Vol

4/15

Options

4/10

EPS Yr

-27.6%

EPS NY

-5.7%

52W%

77%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +44.5% upside

Quality

5/30

Valuation

10/30

Growth

7/25

Stability

6/10

LT Trend

3/5

Upside

+44.5%

Quality

ABCL — P/E HistoricalBiotechnology

AbCellera Biologics Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 562

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

[News_ABCL _Stock]

stock quote shares ABCL – AbCellera Biologics Inc. Stock Price stock today

news today ABCL – AbCellera Biologics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ABCL – AbCellera Biologics Inc. yahoo finance google finance

stock history ABCL – AbCellera Biologics Inc. invest stock market

stock prices ABCL premarket after hours

ticker ABCL fair value insiders trading

ABCL – AbCellera Biologics Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ABCL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y